Dayvigo Cost in South Carolina 2026: Prices, Insurance, and Compounding Options

What Does Dayvigo Actually Cost in South Carolina?

The Eisai manufacturer list price for Dayvigo sits at approximately $320 per month for a 30-tablet supply, but South Carolina cash-pay patients rarely pay that figure. Across SC retail pharmacies in 2026, the average out-of-pocket price is approximately $85 per month when GoodRx-style discount cards or pharmacy savings programs are applied. The gap between list price and street price matters here more than in most drug categories.

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for adults with insomnia characterized by difficulty with sleep onset and/or sleep maintenance [1]. The drug works by blocking orexin OX1 and OX2 receptors, which suppresses the wake-promoting signal rather than broadly sedating the central nervous system. That mechanism sets it apart from benzodiazepines and Z-drugs pharmacologically, which partly explains the premium price point.

The FDA-approved label specifies two doses: 5 mg taken no more than once per night, immediately before bed, with at least seven hours remaining before planned awakening, and 10 mg for patients who tolerate 5 mg but need greater efficacy [2]. Taking it with or immediately after a high-fat meal delays peak concentration by about two hours, so patients in South Carolina who pay for this drug should take it on a relatively empty stomach.

Because lemborexant is a Schedule IV controlled substance under the DEA, South Carolina pharmacies cannot dispense it without a valid prescription. That classification also shapes compounding rules, which are addressed in detail below.

How South Carolina Medicaid Handles Dayvigo Coverage

South Carolina Medicaid does not cover Dayvigo as of 2026. The state's fee-for-service formulary and the managed care organization (MCO) plans administered through SC Healthy Connections Medicaid exclude lemborexant from their preferred drug lists. Medicaid enrollees seeking pharmacologic sleep therapy through SC Healthy Connections are typically directed toward older generic agents.

The SUNRISE-1 trial, published in JAMA Network Open (N=291 adults with insomnia disorder), showed that lemborexant 5 mg and 10 mg both produced statistically significant improvements in subjective sleep onset latency versus placebo at week 1, with effects sustained through 30 days (P<0.001 for both doses) [3]. Despite that evidence base and FDA approval, formulary decisions by state Medicaid programs depend on comparative cost-effectiveness analysis, and Dayvigo has not cleared that bar for SC Medicaid administrators.

Patients enrolled in SC Medicaid who need a covered prescription sleep aid should ask their prescriber about trazodone (off-label, widely covered), doxepin 3 mg or 6 mg (Silenor, sometimes covered), or hydroxyzine. These are not equivalent to lemborexant mechanically, but they represent covered alternatives while patients work on prior authorization appeals or transition to commercial coverage.

If you believe SC Medicaid's exclusion is harming your care, a prescriber can file a prior authorization (PA) request citing medical necessity. PA approvals for excluded drugs are uncommon but not zero. Keep copies of all documentation.

Commercial Insurance Coverage for Dayvigo in South Carolina

Commercial plans in South Carolina vary widely. Blue Cross Blue Shield of South Carolina, State Health Plan (for state employees), Aetna, Cigna, and UnitedHealthcare all maintain their own formularies, and tier placement for Dayvigo shifts year to year.

Dayvigo typically lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) on commercial formularies. A Tier 3 placement commonly means a $50 to $80 per-fill copay after deductible. Tier 4 can push that to $100 or higher per fill. The Eisai Dayvigo Co-Pay Assistance Program can reduce the patient's share to as low as $0 per fill for eligible commercially insured adults, with savings capped at a defined annual maximum [4]. Medicaid, Medicare, and other federal program beneficiaries are not eligible for that card.

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline on behavioral and pharmacological therapies for chronic insomnia states: "We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults" and places orexin antagonists as a class in a recommended treatment category [5]. That guideline position gives prescribers clinical footing when writing PA letters for orexin receptor antagonists including lemborexant.

To check your specific plan before filling, call the member services number on your insurance card and ask:

1. Is lemborexant (brand name Dayvigo, NDC prefix 62856) on the formulary?
2. What tier?
3. Is step therapy required (e.g., must I try zolpidem first)?
4. Is a quantity limit applied (e.g., 30 tablets per 30 days)?

Getting those four answers in writing via the insurer's coverage determination portal saves time during any PA appeal.

Is Compounded Lemborexant Legal in South Carolina?

Compounded lemborexant from a licensed 503A pharmacy is legal in South Carolina. 503A pharmacies compound drugs for individual patients under a valid prescription from a licensed prescriber [6]. South Carolina follows federal law on 503A compounding requirements, which are governed by the Drug Quality and Security Act of 2013 and overseen by the FDA and state boards of pharmacy.

Lemborexant's Schedule IV status does add a layer of complexity. A compounding pharmacy must be licensed to handle Schedule IV controlled substances through the DEA, and the compounding itself must occur in response to a valid patient-specific prescription. Bulk compounding of Schedule IV substances without patient-specific prescriptions is prohibited. When those conditions are met, a licensed 503A pharmacy in South Carolina can legally prepare lemborexant capsules or an oral suspension.

Cost is the primary reason patients explore this route. Compounded lemborexant from a licensed South Carolina 503A pharmacy can run significantly below the $85 retail cash-pay average, with some pharmacies pricing it under $40 per month depending on dose and quantity. The trade-off is that compounded preparations lack the same FDA-reviewed bioequivalence data as the branded Dayvigo tablet [7]. Tablet hardness, dissolution rate, and actual drug content can vary between compounding batches.

The HealthRX clinical team recommends patients considering compounded lemborexant ask any 503A pharmacy four verification questions before ordering: (1) Is the pharmacy DEA-licensed for Schedule IV substances? (2) What is the certificate of analysis source for the lemborexant API? (3) Does the pharmacy perform in-house potency testing? (4) What is the beyond-use date policy? A pharmacy unable to answer all four clearly warrants caution.

How to Get a Dayvigo Prescription via Telehealth in South Carolina

Telehealth prescribing of Dayvigo is permitted in South Carolina. State law allows licensed physicians and advanced practice registered nurses (APRNs) to conduct a remote evaluation and, where clinically appropriate, prescribe Schedule IV controlled substances following a good-faith exam. The DEA's flexibilities originally introduced during the public health emergency have been extended through subsequent rulemakings, though the final permanent rule on telemedicine prescribing of controlled substances continues to evolve [8].

For a telehealth visit to result in a valid Dayvigo prescription in South Carolina, the clinician must:

• Conduct a synchronous audio-visual visit (phone-only is generally insufficient for Schedule IV prescriptions)
• Document a legitimate medical purpose and a bona fide provider-patient relationship
• Comply with South Carolina Board of Medical Examiners regulations on telemedicine

Patients with chronic insomnia disorder who have not tried behavioral interventions may be directed first to cognitive behavioral therapy for insomnia (CBT-I), which the AASM guideline recommends as first-line treatment before pharmacotherapy [5]. Telehealth platforms that prescribe Dayvigo should document CBT-I discussion or prior trial in the medical record.

HealthRX telehealth visits for insomnia include a structured sleep history, Insomnia Severity Index (ISI) scoring, and screening for obstructive sleep apnea before any pharmacologic prescription is generated.

SUNRISE Trials: The Evidence Behind Lemborexant

Understanding the evidence helps South Carolina patients make informed decisions and gives prescribers ammunition for insurance appeals. Two key trials established the Dayvigo approval package.

SUNRISE-1 (N=291), published in JAMA Network Open in 2019, compared lemborexant 5 mg and 10 mg against placebo and against zolpidem extended-release 6.25 mg in adults aged 55 and older with insomnia disorder [3]. Both lemborexant doses outperformed placebo on polysomnographic sleep onset latency (sSOL) at week 1. Lemborexant 10 mg also outperformed zolpidem ER on several sleep maintenance endpoints. The JAMA Network Open publication reported that morning sleepiness scores were significantly lower with lemborexant than with zolpidem ER, a clinically meaningful finding for patients who drive or operate machinery [3].

SUNRISE-2 (N=949), a 12-month randomized trial, demonstrated that the improvements in subjective sleep onset latency and wake after sleep onset were maintained without evidence of tolerance over the full year [9]. The study found that lemborexant 5 mg reduced subjective WASO by a mean of 27.4 minutes versus 7.4 minutes for placebo at month 6 (P<0.001) [9]. The FDA reviewed both trials as part of the New Drug Application that led to approval in December 2019 [2].

Rebound insomnia on discontinuation was assessed in SUNRISE-2. The trial found no statistically significant rebound effect after abrupt discontinuation at 12 months, which distinguishes lemborexant from benzodiazepines in the discontinuation profile [9]. That finding is especially relevant for patients using it short-term through a telehealth platform.

How the Eisai Co-Pay Card Works in South Carolina

Eisai's Dayvigo Co-Pay Assistance Program is available to commercially insured South Carolina residents who meet eligibility criteria [4]. The card reduces the patient's out-of-pocket cost per fill, with some patients paying as little as $0, subject to a program maximum per calendar year.

Enrollment works like this. The patient or prescriber visits the Eisai patient support page, completes an online enrollment form, and receives a card number or electronic benefit. At the SC retail pharmacy, the pharmacist runs the primary insurance claim first, then applies the co-pay card as secondary. The card cannot be used if the primary payer is Medicare Part D, Medicaid, TRICARE, or any other federal program [4].

The annual maximum benefit means the card covers co-pays up to a defined dollar ceiling. After that ceiling is reached in a given calendar year, the patient pays the plan's standard cost-sharing. Patients who start Dayvigo in January and use it continuously tend to exhaust the benefit by late summer or fall, depending on the tier.

South Carolina patients on the State Health Plan (SHP) for state employees face a distinct formulary structure managed through Express Scripts. Dayvigo's tier placement under the SHP is subject to annual formulary review and may differ from individual commercial plans. Checking the SHP drug search tool each January is worth doing.

Practical Cost Comparison for South Carolina Patients in 2026

Putting the numbers together gives a clearer picture. Below is what a South Carolina patient might realistically pay per month depending on their situation.

Cash-pay with a GoodRx-type discount card: approximately $85 per month. This is the average across SC retail pharmacies and represents the floor for most patients without insurance coverage.

Commercially insured, Tier 3, with Eisai co-pay card: potentially $0 per month up to the program annual maximum. After the maximum is reached, the patient pays the Tier 3 copay, typically $50 to $80.

Commercially insured, Tier 4, no co-pay card: $100 or more per month depending on plan design.

SC Medicaid: not covered. Cash-pay or compounding is the only route.

Compounded lemborexant from a licensed 503A SC pharmacy: varies, but pricing under $40 per month is available from some pharmacies. Verify DEA Schedule IV licensure and API sourcing before ordering.

Medicare Part D: lemborexant is on some Part D formularies at Tier 4 or Tier 5. Co-pay card is not applicable. The Medicare Extra Help (Low Income Subsidy) program may reduce cost for qualifying beneficiaries. The Social Security Administration administers Extra Help eligibility [10].

Safety Considerations That Affect Dosing and Cost Calculations

Dose selection affects cost. Patients who respond adequately to 5 mg spend less per month than those who require 10 mg, because both doses come in a 30-tablet supply at similar pricing tiers. Starting at 5 mg is the FDA-recommended starting dose and represents the lower-cost path when it works [2].

Lemborexant is contraindicated in patients with narcolepsy. The FDA label warns of complex sleep behaviors including sleepwalking and sleep-driving, which have been reported with orexin receptor antagonists, and advises prescribers to counsel patients to avoid alcohol because additive CNS depression may occur [2].

Cytochrome P450 3A (CYP3A) inhibitors, including azole antifungals like fluconazole and some HIV medications, can increase lemborexant plasma concentrations substantially. The label recommends against use with strong or moderate CYP3A inhibitors [2]. Patients taking these medications in South Carolina should discuss dose adjustments or alternative agents with their prescriber before paying for a month of Dayvigo.

Hepatic impairment also changes the calculus. Mild hepatic impairment requires no dose change, but moderate impairment limits dosing to 5 mg nightly. Severe hepatic impairment is a contraindication [2]. Knowing this before filling helps patients avoid paying for 10 mg tablets that their prescriber will need to change.

Comparing Dayvigo to Other Insomnia Medications Available in South Carolina

Lemborexant competes in a category that now includes two other orexin receptor antagonists: suvorexant (Belsomra, approved 2014) and seltorexant (not yet FDA-approved as of this writing). It also competes with generic zolpidem, which costs under $10 per month at SC retail pharmacies, and with trazodone, which is similarly cheap.

The AASM guideline notes a conditional recommendation for suvorexant for sleep maintenance insomnia [5]. Lemborexant received FDA approval based partly on superior tolerability data compared with zolpidem ER in SUNRISE-1 [3]. Whether that clinical advantage justifies the cost difference relative to $10 generic zolpidem is a conversation between the patient and prescriber, factoring in prior response, fall risk, next-day driving, and comorbidities.

Chronic insomnia disorder affects approximately 10 to 15 percent of the U.S. adult population according to CDC surveillance data [11]. In South Carolina, that translates to roughly 400,000 to 600,000 adults, many of whom cycle through multiple treatments before finding an effective option. Cost is one of the most common reasons cited for discontinuation.

Accessing Dayvigo Through HealthRX in South Carolina

HealthRX operates telehealth services in South Carolina and can prescribe lemborexant to eligible patients following a comprehensive sleep evaluation. Visits are conducted via synchronous video, consistent with SC Board of Medical Examiners requirements for controlled substance prescribing via telemedicine [8].

The HealthRX intake process includes an Insomnia Severity Index assessment, a structured sleep history, and screening questions for conditions that would contraindicate lemborexant, including narcolepsy, severe hepatic disease, and current use of strong CYP3A inhibitors. Patients who screen positive for likely obstructive sleep apnea based on STOP-BANG criteria are referred for sleep study evaluation before a sedative-hypnotic prescription is generated, consistent with standard clinical practice.

After a prescription is issued, the HealthRX care team can assist with co-pay card enrollment for commercially insured patients and provide 503A pharmacy referrals for patients seeking the compounding route. South Carolina patients paying cash can expect the $85 per month retail average, though shopping among SC pharmacies using discount card platforms can sometimes lower that figure by $10 to $20.